Last reviewed · How we verify
ZX-7101A for oral suspension
ZX-7101A for oral suspension is a HIF-1α inhibitor Small molecule drug developed by Nanjing Zenshine Pharmaceuticals. It is currently in Phase 3 development for Metastatic non-small cell lung cancer, PD-L1 positive, Metastatic renal cell carcinoma.
ZX-7101A is a small molecule that targets the HIF-1α pathway.
ZX-7101A is a small molecule that targets the HIF-1α pathway. Used for Metastatic non-small cell lung cancer, PD-L1 positive, Metastatic renal cell carcinoma.
At a glance
| Generic name | ZX-7101A for oral suspension |
|---|---|
| Sponsor | Nanjing Zenshine Pharmaceuticals |
| Drug class | HIF-1α inhibitor |
| Target | HIF-1α |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
By inhibiting HIF-1α, ZX-7101A aims to reduce tumor growth and angiogenesis. This mechanism is thought to be beneficial in treating various types of cancer.
Approved indications
- Metastatic non-small cell lung cancer, PD-L1 positive
- Metastatic renal cell carcinoma
Common side effects
- Fatigue
- Nausea
- Diarrhea
Key clinical trials
- Study to Assess the Safety and Efficacy of ZX-7101A for Oral Suspension in Chinese Pediatric Participants 2 to 11 Years of Age With Influenza (PHASE3)
- Study to Assess the Safety and Efficacy of ZX-7101A in Children Aged 5-11 Years With Influenza (PHASE3)
- Study to Evaluate the Pharmacokinetics and Relative Bioavailability of Metabolites in Healthy Chinese Adult Males (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ZX-7101A for oral suspension CI brief — competitive landscape report
- ZX-7101A for oral suspension updates RSS · CI watch RSS
- Nanjing Zenshine Pharmaceuticals portfolio CI
Frequently asked questions about ZX-7101A for oral suspension
What is ZX-7101A for oral suspension?
How does ZX-7101A for oral suspension work?
What is ZX-7101A for oral suspension used for?
Who makes ZX-7101A for oral suspension?
What drug class is ZX-7101A for oral suspension in?
What development phase is ZX-7101A for oral suspension in?
What are the side effects of ZX-7101A for oral suspension?
What does ZX-7101A for oral suspension target?
Related
- Drug class: All HIF-1α inhibitor drugs
- Target: All drugs targeting HIF-1α
- Manufacturer: Nanjing Zenshine Pharmaceuticals — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Metastatic non-small cell lung cancer, PD-L1 positive
- Indication: Drugs for Metastatic renal cell carcinoma